Last reviewed · How we verify

Marjan Industria e Comercio ltda — Portfolio Competitive Intelligence Brief

Marjan Industria e Comercio ltda pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Valeriana Valeriana marketed Standardized Chemical Allergen [EPC] Other
Passiflora ; Crataegus and Salix Passiflora ; Crataegus and Salix phase 3 Herbal combination / Phytotherapeutic agent Cardiovascular / Anxiolytic

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Bionorica SE · 1 shared drug class
  3. Deseret Biologicals, Inc. · 1 shared drug class
  4. Donat R. Spahn · 1 shared drug class
  5. Dr. Laurence Klotz · 1 shared drug class
  6. Millet Roux · 1 shared drug class
  7. Nantes University Hospital · 1 shared drug class
  8. Nutritional Specialties, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Marjan Industria e Comercio ltda:

Cite this brief

Drug Landscape (2026). Marjan Industria e Comercio ltda — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/marjan-industria-e-comercio-ltda. Accessed 2026-05-15.

Related